Thelansis

 Hereditary angioedema (HAE) is a genetic disease characterized by the occurrence of transitory and recurrent subcutaneous and/or submucosal edemas resulting in swelling and/or abdominal pain. Three types of HAE have been described. ·        Hereditary Angioedema (HAE) is estimated to affect 1 in 50,000 people. Type I is the most common, accounting for 85 per cent of cases. Type II occurs in 15 per cent of cases, and type III is very rare Thelansis’s “Hereditary Angioedema (HAE) Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hereditary Angioedema (HAE) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China)....